HC Wainwright Reaffirms Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $5.75 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 90.40% from the company’s previous close.

Separately, BTIG Research assumed coverage on VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 price target for the company.

VYNE Therapeutics Trading Down 12.0 %

NASDAQ:VYNE opened at $3.02 on Tuesday. The stock has a market capitalization of $44.55 million, a PE ratio of -3.51 and a beta of 1.30. VYNE Therapeutics has a 1-year low of $1.57 and a 1-year high of $4.30. The firm has a fifty day simple moving average of $2.99 and a 200 day simple moving average of $2.35.

Institutional Trading of VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics comprises 0.0% of Lynx1 Capital Management LP’s portfolio, making the stock its 17th largest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.